Cardiorenal Differences Among NSAIDs and Coxibs: Real-World ExperienceByEdmund H. Sonnenblick, MDOctober 1st 2002
Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis PatientsByAndrew Whelton,John G. Fort,Joseph A. Puma,Diane Normandin,Alfonso E. Bello,Kenneth M. Verburg, for the SUCCESS VI Study Group (Reprinted from ThOctober 1st 2002
Prevalence of Cardiovascular Disease Risk Factors Among US Adults With Self-Reported Osteoarthritis: Data from the Third National Health and Nutrition Examination SurveyByGurkirpal Singh, MD,Jeffrey D. Miller, MS,Fleur H. Lee, MPH,Dan Pettitt, DVM, MSc,Mason W. Russell, MAPEOctober 1st 2002
Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life PracticeBySean Z. Zhao, MD, PhD,Thomas A. Burke, PharmD, MPH,Andrew Whelton, MD, PhD,Heather von Allmen,Scott C. Henderson, MSOctober 1st 2002
Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific InhibitorsBySean Z. Zhao, MD, PhD,Thomas A. Burke, PharmD, MPH,Andrew Whelton, MD, PhD,Heather von Allmen,Scott C. Henderson, MSOctober 1st 2002
Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific InhibitorsBySean Z. Zhao, MD, PhD,Thomas A. Burke, PharmD, MPH,Andrew Whelton, MD, PhD,Heather von Allmen,Scott C. Henderson, MSOctober 1st 2002
Differences Between COX-2-Specific Inhibitors: Clinical and Economic ImplicationsByEdmund H. Sonnenblick, MDOctober 1st 2002
